Swiss MedTech 2026
MedTech in Recalibration: Staying Ahead in Regulation, AI, and the Deal Landscape

Sidley, ISS AG, and Swiss Medtech invite you to our annual Swiss MedTech afternoon, bringing together regulators, industry leaders, legal thought leaders, and scientific advisers to exchange insights on the evolving MedTech landscape.

2026 is a pivotal year for Swiss and European MedTech. MDR and IVDR revisions are progressing, while the AI Act timeline for medical devices has been adjusted under the Digital Omnibus agreement.

At the same time, EU simplification initiatives are reshaping sustainability, digitalization, and reporting obligations.

Manufacturers also face growing geopolitical and economic pressures, including supply chain disruption, trade uncertainty, and rising costs.

In Switzerland, proposed Swissmedic supervisory fees, the TPITO revision and the rollout of swissdamed are adding further complexity, while increased M&A activity continues to reshape the sector.

Key highlights on the agenda include:

• The European Regulatory Reset: Navigating MDR/IVDR Revision and Omnibus
  What is changing, what is at stake, and how Swiss manufacturers should prepare for the next phase of the European regulatory framework.
• Operational Resilience in a Volatile Market Environment
  How trade tensions, supply chain dependencies, sustainability and PFAS-related requirements, and regulatory change are influencing manufacturing, sourcing, and long-term decisions.
• Switzerland: Additional Economic Pressure on Manufacturers
  Swissmedic supervisory fees, swissdamed implementation, proposed TPITO revisions, and evolving anti-corruption expectations — and what they mean for Swiss manufacturers.
• AI Act: From Uncertainty to Implementation
  The revised timeline for AI-enabled medical devices and the practical implications for MDSW strategy, data governance, and compliance planning.
• Strategic Deals in MedTech
  How AI, market access, supply chain resilience, and regulatory complexity are reshaping acquisition strategies, valuations, and investment decisions. 

Who should attend?

Executives, investors, in-house counsel, and regulatory managers interested in and/or facing regulatory issues in Switzerland.

For more information or questions, please contact Geneva Events.